What is Dysport®?

For the temporary improvement of moderate to severe glabellar lines

Dysport is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients less than 65 years of age.

More reasons to be confident in Dysport

The Dysport legacy

U.S. clinical experience1,2:

  • Dysport was studied for safety in more than 2,400 U.S. aesthetic patients
    • Studied for efficacy in a subset of 376 patients1
  • In long-term safety analysis of repeat administrations, over 6,700 treatments were administered to evaluate the safety of Dysport
    • Over approximately 24 months, 1,415 patients were evaluated2
  • Approved for aesthetic use in 57 countries3

Dysport. Another option for your patients.

Before + after at maximum frown

Picture before Dysport® treatment Improved glabellar lines after Dysport® treatment image
Frown Before Dysport Treatment
Frown after 50 units, Day 10
Individual results may vary.

Dysport is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients less than 65 years of age.

Facial Anatomy in the Treatment of Glabellar Lines

  • Caution should be exercised when administering Dysport to patients with surgical alterations to the facial anatomy, excessive weakness or atrophy in the target muscle(s), marked facial asymmetry, inflammation at the injection site(s), ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin or the inability to substantially lessen glabellar lines by physically spreading them apart.
  • Do not exceed the recommended dosage and frequency of administration of Dysport. In clinical trials, subjects who received a higher dose of Dysport had an increased incidence of eyelid ptosis.

View clinical efficacy data

Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.
See below for Dysport Important Safety Information and Full Prescribing Information including Boxed Warning.

References
  1. Dysport Prescribing Information. Galderma Laboratories, L.P. Fort Worth, TX. July 2015.
  2. Cohen JL, Schlessinger J, Cox SE, Lin X, for the Reloxin Investigational Group. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J. 2009;29:S43–S49.
  3. Ipsen. Dysport Cosmesis Global Indications, May 2012. Data on file, Galderma Laboratories, L.P.
Picture before Dysport® treatment Before Dysport injection image Before forehead injection Before glabellar lines treatment Before glabellar lines injection frown lines injection before picture Improved glabellar lines after Dysport® treatment image Image after Dysport injection After forehead injection picture Frown after Dysport Frown lines injection after image frown lines injection after picture

IMPORTANT SAFETY INFORMATION

Indication: Dysport is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients less than 65 years of age.

Distant Spread of Toxin Effect
Postmarketing reports indicate that the effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

CONTRAINDICATIONS

DOSAGE AND ADMINISTRATION

The potency Units of Dysport are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of Dysport cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

WARNINGS AND PRECAUTIONS

Facial Anatomy in the Treatment of Glabellar Lines

Pre-existing Neuromuscular Disorders

Human Albumin

Intradermal Immune Reaction

ADVERSE REACTIONS

DRUG INTERACTIONS

USE IN SPECIFIC POPULATIONS

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see Dysport Full Prescribing Information, including Medication Guide.